Complete pathological response of hepatocellular carcinoma with systemic combination chemotherapy

Anti-Cancer Drugs

Volumn 19, Issue 8, 2008, Pages 837-840

  Ferrari, Daris ^a   Di Maria, Giuseppe ^a   Fazio, Nicola ^b   Codecà, Carla ^a   Fiore, Jessica ^a   Luciani, Andrea ^a   Oldani, Sabina ^a   Maggioni, Marco ^c   Foa, Paolo ^a  

^a SAN PAOLO HOSPITAL   (Italy)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^c FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

ECF regimen; Hepatocellular carcinoma; Systemic chemotherapy

Indexed keywords

CISPLATIN; EPIRUBICIN; FLUOROURACIL; ALPHA FETOPROTEIN; ANTINEOPLASTIC AGENT; FPEPIR REGIMEN;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CASE REPORT; CHEMOSENSITIVITY; CHOLECYSTECTOMY; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER RESECTION; LUNG NODULE; MULTIPLE CYCLE TREATMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; ADJUVANT CHEMOTHERAPY; LIVER FUNCTION TEST; LIVER TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY;

ALPHA-FETOPROTEINS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; CHEMOTHERAPY, ADJUVANT; CISPLATIN; EPIRUBICIN; FEMALE; FLUOROURACIL; HUMANS; LIVER FUNCTION TESTS; LIVER NEOPLASMS; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 53749103405     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32830c2380     Document Type: Article

References (29)

1. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340:745-750.
2. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics. CA Cancer J Clin 2007; 57:43-66.
3. NCCN Practice Guidelines in Oncology - Hepatobiliary Cancer v.2.2008.
4. Tang ZY, Yu YQ, Zhou XD. Evolution of surgery in the treatment of hepatocellular carcinoma from the 1950s to the 1990s. Semin Surg Oncol 1993; 9 :293-297.
5. Bruix J, Castells A, Bosch J, Feu F, Fuster J, Garcia-Pagan JC, et al. Surgical resection of hepatocellular carcinoma in cirrhotic patients. Prognostic value of preoperative portal pressure. Gastroenterology 1996; 111:1018-1022.
6. Makuuchi M. Surgical treatment for hepatocellular carcinoma. In: Arroyo V, Bosch J, Rode's J, editors. Treatments in hepatology. Barcelona: Masson; 1995. pp. 341-352.
7. Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 1999; 30:1434-1440.
8. Lin DY, Lin SM, Liaw YF. Non-surgical treatment of hepatocellular carcinoma. J Gastroenterol Hepatol 1997; 12:S319-S328.
9. Lo CM, Ngan H, Tso WK, Li CL, Lam CM, Poon RT, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35:1164-1171.
10. Llovet JM, Real MI, Montana X; for the Barcelona Clinic Liver Cancer Group. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomized controlled trial. Lancet 2002; 359:1734-1739.
11. Kotoh K, Sakai H, Sakamoto S, Nakayama S, Satoh M, Morotumi I, et al. The effect of percutaneous ethanol injection therapy on small solitary hepatocellular carcinoma is comparable to that of hepatectomy. Am J Gastroenterol 1994; 89:194-198.
12. Pawarode A, Voravud N, Sriuranpong V, Kullavanijaya P, Patt YZ. Natural history of untreated primary hepatocellular carcinoma: a retrospective study of 157 patients. Am J Clin Oncol 1998; 21:386-391.
13. Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment: study of 850 patients. Cancer (Phila) 1985; 56:918-928.
14. Lai CL, Wu PC, Chan GC, Lok AS, Lin HJ. Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial. Cancer 1988; 62:479-483.
15. Yeo W, Mok TS, Zee B, Leung TW, Lai PB, Lau WY, et al. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha 2b/ doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst 2005; 97:1532-1538.
16. Patt YZ, Hoque A, Roh M, Ellis L, Lozano R, Carrasco CH, et al. Durable clinical and pathologic response of hepatocellular carcinoma to systemic and hepatic arterial administration of platinol, recombinant interferon alpha 2B, doxorubicin, and 5-fluorouracil: a communication. Am J Clin Oncol 1999; 22:209-213.
17. Nzeako UC, Goodman ZD, Ishak GK. Hepatocellular carcinoma in cirrhotic and noncirrhotic livers. A clinico-histopathologic study of 804 North American patients. Am J Clin Pathol 1996; 105:65-75.
18. The Cancer of Liver Italian Program (CLIP) Investigators. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients. Hepatology 1998; 28:751-755.
19. Boucher E, Corbinais S, Brissot P, Boudjema K, Raoul J. Treatment of hepatocellular carcinoma (HCC) with systemic chemotherapy combining epirubicin, cisplatinum and infusional 5-fluorouracil (ECF regimen). Cancer Chemother Pharmacol 2002; 50:305-308.
20. Chou YY, Cheng AL, Hsu HC. Expression of P-glycoprotein and p53 in advanced hepatocellular carcinoma treated by single agent chemotherapy: clinical correlation. J Gastroenterol Hepatol 1997; 12:569-575.
21. Leung T, Tang A, Zee B, Yu S, Lai P, Lau W, Johnson P. Factor predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy. Cancer 2002; 94:420-427.
22. Ihde DC, Matthews MJ, Makuch RW, McIntire KR, Eddy JL, Seeff LB. Prognostic factors in patients with hepatocellular carcinoma receiving systemic chemotherapy. Identification of two groups of patients with prospects for prolonged survival. Am J Med 1985; 78:399-406.
23. Boige V, Täieb J, Hebbar M, Malka D, Debaere T, Hannoun L, et al. Irinotecan as first-line chemotherapy in patients with advanced hepatocellular carcinoma: a multicenter phase II study with dose adjustment according to baseline serum bilirubin level. Eur J Cancer 2006; 42: 456-459.
24. Li S, Niu Z, Tian H, Zhang B, Wang F, Yi LH, Yu J. Treatment of advanced hepatocellular carcinoma with gemcitabine plus oxaliplatin. Hepatogastroenterology 2007; 54:218-223.
25. Ulrich-Pur H, Kornek GV, Fiebiger W, Schüll B, Raderer M, Scheithauer W. Treatment of advanced hepatocellular carcinoma with biweekly high-dose gemcitabine. Oncology 2001; 60:313-315.
26. Zhu AX, Blaszkowsky LS, Ryan DP, Clark JW, Muzikansky A, Horgan K, et al. Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006; 24:1898-1903.
27. Jang JW, Park YM, Bae SH, Choi JY, Yoon SK, Chang UI, et al. Therapeutic efficacy of multimodal combination therapy using transcatheter arterial infusion of epirubicin and cisplatin, systemic infusion of 5-fluorouracil, and additional percutaneous ethanol injection for unresectable hepatocellular carcinoma. Cancer Chemother Pharmacol 2004; 54:415-420.
28. Leung TW, Blaszkowsky LS, Ryan DP, Clark JW, Muzikansky A, Horgan K, et al. Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. Clin Cancer Res 1999; 5: 1676-1681.
29. Quek R, Lim ST, Ong S. Hepatocellular carcinoma: pathological complete response to oral capecitabine, megestrol and thalidomide. Acta Oncol 2006; 45:95-97.